Evidence map›Paper›PMID 40089604›Full record

ArticleMolecular psychiatry2025

Shank3 modulates Rpl3 expression and protein synthesis via mGlu5: implications for Phelan McDermid syndrome.

Federica Giona, Stefania Beretta, Antonio Zippo, Alessia Stefanoni, Zaira Tomasoni, Cinzia Vicidomini, Luisa Ponzoni, Mariaelvina Sala, Carrie K Jones, P Jeffrey Conn and 3 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Federica Giona *CNR, Neuroscience Institute, Milano, Italy.
Stefania Beretta *CNR, Neuroscience Institute, Milano, Italy.
Antonio ZippoCNR, Neuroscience Institute, Milano, Italy.ORCID 0000-0001-8421-7554
Alessia StefanoniCNR, Neuroscience Institute, Milano, Italy.
Zaira TomasoniCNR, Neuroscience Institute, Milano, Italy.
Cinzia VicidominiCNR, Neuroscience Institute, Milano, Italy.
Luisa PonzoniCNR, Neuroscience Institute, Milano, Italy.
Mariaelvina SalaCNR, Neuroscience Institute, Milano, Italy.ORCID 0000-0001-9310-958X
Carrie K JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
P Jeffrey ConnWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, 37232, USA.
Tobias M BoeckersUlm Site, DZNE, Ulm, Germany.ORCID 0000-0002-1486-8535
Carlo SalaCNR, Neuroscience Institute, Milano, Italy.ORCID 0000-0003-0662-9523
Chiara VerpelliCNR, Neuroscience Institute, Milano, Italy. chiara.verpelli@in.cnr.it.ORCID 0000-0003-2949-9725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations or deletions in the SHANK3 gene have been identified in up to 1% of autism spectrum disorder cases and are considered the primary cause of neuropsychiatric symptoms in Phelan McDermid syndrome (PMS). While synaptic dysfunctions have been extensively documented in the absence of Shank3, other mechanisms through which Shank3 may regulate neuronal functions remain unclear. In this study, we report that the ribosomal protein Rpl3 and overall protein synthesis are downregulated in the cortex and striatum of Shank3 knockout (KO) mice and in neurons differentiated from human-induced pluripotent stem cells (hiPSCs) derived from a PMS patient. Moreover, restoring Rpl3 expression in the striatum of Shank3 KO mice was sufficient to rescue protein synthesis and mitigate excessive grooming, suggesting that the behavioral alterations observed in Shank3 KO mice might be, at least in part, caused by Rpl3 downregulation and consequent impaired protein synthesis. Furthermore, we demonstrated that chronic inhibition of mGlu5 is sufficient to reduce Rpl3 expression, which in turn impairs global protein synthesis. Consequently, chronic treatment with VU0409551, a potent and selective mGlu5 positive allosteric modulator, rescues Rpl3 expression and the resulting reduction in protein synthesis, leading to long-lasting improvements in behavioral deficits in Shank3 KO mice Altogether, we propose a new role for Shank3 in modulating Rpl3 protein expression, ribosomal function, and protein synthesis by downregulating mGlu5 receptor activity.

Indexed as

Chromosome DisordersNerve Tissue ProteinsReceptor, Metabotropic Glutamate 5Ribosomal ProteinsAnimalsAutism Spectrum DisorderCerebral CortexChromosome DeletionChromosomes, Human, Pair 22Corpus StriatumDisease Models, AnimalDown-RegulationHumansInduced Pluripotent Stem CellsMaleMiceMicrofilament ProteinsNerve Tissue ProteinsReceptor, Metabotropic Glutamate 5Ribosomal ProteinsSHANK3 protein, humanShank3 protein, mouse

Identifiers

PMID40089604
PMCPMC12240844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.